Vivo Bio Tech

Which are the latest news on Vivo Bio Tech?

Why is Vivo Bio Tech Ltd falling/rising?

As of 05-Sep, Vivo Bio Tech Ltd's stock price is currently at 18.92, showing a short-term gain despite a significant year-to-date decline of 40.11%. The stock has outperformed its sector today but has mixed performance indicators over longer periods.

As of 05-Sep, Vivo Bio Tech Ltd's stock price is rising, currently at 18.92, with a change of 0.13 (0.69%) upward. The stock has shown a positive performance today, outperforming its sector by 1.04%. Additionally, it has been gaining for the last three days, accumulating a total return of 3.28% during this period. <BR><BR>Despite this recent upward movement, it is important to note that the stock has experienced significant declines over longer periods, with a year-to-date drop of 40.11% and a 1-year decline of 48.43%. The stock is currently trading higher than its 5-day moving averages, although it remains below the 20-day, 50-day, 100-day, and 200-day moving averages, indicating mixed performance in the context of longer-term trends. <BR><BR>Investor participation has been decreasing, as evidenced by a 4.07% decline in delivery volume compared to the 5-day average. However, the stock remains liquid enough for trading, based on its average traded value. Overall, the recent rise in Vivo Bio Tech Ltd's stock price can be attributed to short-term gains despite the broader context of longer-term declines.

Who are in the management team of Vivo Bio Tech?

The management team of Vivo Bio Tech includes Kalyan Ram Mangipudi, Alangudi Sankaranarayanan, K Sunder, Hariharan Ravindran, Kunda Kalpana, Karopadi Shivanand Nayak, K Sri Kalyan, and Shyam Sunder Tipparaju, bringing diverse expertise and leadership to the company.

The management team of Vivo Bio Tech includes the following members:<BR><BR>1. Kalyan Ram Mangipudi - Whole-time Director<BR>2. Alangudi Sankaranarayanan - Whole-time Director<BR>3. K Sunder - Chairman & Independent Director<BR>4. Hariharan Ravindran - Independent Director<BR>5. Kunda Kalpana - Independent Director<BR>6. Karopadi Shivanand Nayak - Director<BR>7. K Sri Kalyan - Whole Time Director & CFO<BR>8. Shyam Sunder Tipparaju - Additional Director<BR><BR>This team brings a diverse range of expertise and leadership to the company.

What does Vivo Bio Tech do?

Vivo Bio Tech Ltd is a Contract Research Organization (CRO) that offers drug development and discovery services to pharmaceutical and biotech companies. As of June 2026, it reported net sales of 14 Cr and a market cap of INR 40 Cr.

Overview: <BR>Vivo Bio Tech Ltd is a full-service Contract Research Organization (CRO) that provides drug development and discovery services to pharmaceutical and biotech companies worldwide, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap.<BR><BR>History: <BR>Vivo Bio Tech Limited was established in February 1987. The latest quarterly results reported net sales and net profit for the period ending June 2026.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 14 Cr (Quarterly Results - Jun 2026) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Jun 2026) <BR>Market-cap value: INR 40 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.72 <BR>Return on Equity: -1.86% <BR>Price to Book: 0.45<BR><BR>Contact Details: <BR>Address: Survey #349/A Pregnapur Vlge, Gajel Telangana: 502311 <BR>Email: investors@vivobio.com <BR>Website: http://www.vivobio.com

Who are the peers of the Vivo Bio Tech?

Vivo Bio Tech's peers include Shelter Pharma, Vasundhara Rasy., Mangalam Drugs, Kabra Drugs, Parmax Pharma, ANG Lifesciences, Rajnish Wellness, Roopa Industries, and Murae Organisor. In terms of management risk, Vivo Bio Tech is rated below average, with a 1-year return of -49.05%, better than Mangalam Drugs but worse than Parmax Pharma, which has the highest return at 273.20%.

Peers: The peers of Vivo Bio Tech are Shelter Pharma, Vasundhara Rasy., Mangalam Drugs, Kabra Drugs, Parmax Pharma, ANG Lifesciences, Rajnish Wellness, Roopa Industries, and Murae Organisor.<BR><BR>Quality Snapshot: Excellent management risk is observed at Shelter Pharma, while Average management risk is found at Vasundhara Rasy. and Rajnish Wellness, and the rest. Below Average management risk is noted for Mangalam Drugs, Kabra Drugs, Parmax Pharma, ANG Lifesciences, Vivo Bio Tech, Roopa Industries, and Murae Organisor. Growth is rated as Excellent for Kabra Drugs and Roopa Industries, Good for Shelter Pharma and Murae Organisor, while Below Average growth is seen in Vasundhara Rasy., Mangalam Drugs, Parmax Pharma, ANG Lifesciences, Rajnish Wellness, and Vivo Bio Tech. Capital Structure is rated as Excellent for Shelter Pharma, Good for Vasundhara Rasy., and Below Average for Mangalam Drugs, Kabra Drugs, Parmax Pharma, ANG Lifesciences, Rajnish Wellness, Vivo Bio Tech, Roopa Industries, and Murae Organisor.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Parmax Pharma at 273.20%, while the lowest is Mangalam Drugs at -57.20%. Vivo Bio Tech's 1-year return of -49.05% is better than Mangalam Drugs but worse than Parmax Pharma. Additionally, the six-month return is negative for Shelter Pharma, Kabra Drugs, Rajnish Wellness, Vivo Bio Tech, and Murae Organisor.

How big is Vivo Bio Tech?

As of 31st August, Vivo Bio Tech Ltd has a market capitalization of 40.00 Cr and reported net sales of 55.10 Cr with a net loss of 2.85 Cr over the latest four quarters. Shareholder's funds were 77.90 Cr and total assets were valued at 143.23 Cr as of March 2025.

As of 31st August, Vivo Bio Tech Ltd has a market capitalization of 40.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Vivo Bio Tech reported net sales of 55.10 Cr. However, it experienced a loss of 2.85 Cr in net profit during the same period.<BR><BR>The latest annual period for the balance sheet is March 2025, where shareholder's funds amounted to 77.90 Cr and total assets were valued at 143.23 Cr.

Are Vivo Bio Tech Ltd. latest results good or bad?

Vivo Bio Tech Ltd.'s latest Q1 FY27 results show a 14.15% revenue growth to ₹14.28 crores, but a concerning 85.82% drop in net profit to ₹0.19 crores and declining margins indicate serious profitability issues, suggesting a challenging outlook for investors.

Vivo Bio Tech Ltd.'s latest results for Q1 FY27 present a mixed picture, but overall, the performance raises significant concerns. While the company achieved a year-on-year revenue growth of 14.15%, reaching ₹14.28 crores, this top-line growth is overshadowed by a drastic decline in profitability. The net profit plummeted by 85.82% year-on-year to just ₹0.19 crores, indicating serious issues with the company's ability to convert revenue into profit.<BR><BR>The operating margin also contracted sharply from 43.80% to 35.36%, reflecting deteriorating operational efficiency. Additionally, the PAT margin fell to a mere 1.33% from 10.71% in the same quarter last year, highlighting a severe profitability crisis.<BR><BR>The company's effective tax rate of 44.12% further complicates the situation, indicating potential tax inefficiencies that are impacting net profitability. Despite a return to profitability after a loss in the previous quarter, the recovery is weak and insufficient to inspire confidence among investors.<BR><BR>In summary, while Vivo Bio Tech has shown some revenue growth, the significant drop in net profit and margins suggests that the company's financial health is deteriorating. This combination of factors points to a challenging outlook, and investors may need to approach the stock with caution.

When is the next results date for Vivo Bio Tech Ltd.?

The next results date for Vivo Bio Tech Ltd. is 13 July 2026.

The next results date for Vivo Bio Tech Ltd. is scheduled for 13 July 2026.

Should I buy, sell or hold Vivo Bio Tech Ltd.?

How has been the historical performance of Vivo Bio Tech?

Vivo Bio Tech has experienced fluctuating net sales, declining from INR 55.83 crore in March 2019 to INR 46.67 crore in March 2025, but profitability improved significantly, with profit after tax rising to INR 7.28 crore in March 2025. Despite operational challenges, the company has shown an ability to increase operating profit and total assets during this period.

Answer:<BR>The historical performance of Vivo Bio Tech shows a fluctuating trend in net sales and profitability over the years, with a notable increase in profit after tax in the latest fiscal year.<BR><BR>Breakdown:<BR>Vivo Bio Tech's net sales have shown a decline from INR 55.83 crore in March 2019 to INR 46.67 crore in March 2025, with a slight increase from INR 45.45 crore in March 2024. The total operating income followed a similar trend, peaking at INR 52.23 crore in March 2023 before dropping to INR 46.67 crore in March 2025. The total expenditure, excluding depreciation, decreased from INR 42.88 crore in March 2020 to INR 26.16 crore in March 2025, contributing to an increase in operating profit, which rose from INR 12.47 crore in March 2020 to INR 25.31 crore in March 2025. Profit before tax also saw a significant rise, reaching INR 8.79 crore in March 2025, up from INR 4.06 crore in March 2024. Consequently, profit after tax surged to INR 7.28 crore in March 2025, compared to INR 2.53 crore in March 2024. The company's total assets increased from INR 62.14 crore in March 2020 to INR 143.23 crore in March 2025, while total liabilities also rose from INR 62.14 crore to INR 46.29 crore during the same period. Cash flow from operating activities decreased to INR 11 crore in March 2025, down from INR 15 crore in March 2024, while cash flow from investing activities turned negative at INR -15 crore. Overall, Vivo Bio Tech has demonstrated a capacity for profitability despite fluctuations in sales and operational challenges.

Is Vivo Bio Tech overvalued or undervalued?

As of May 26, 2025, Vivo Bio Tech is considered very attractive and undervalued with a PE ratio of 9.33, an EV to EBITDA ratio of 5.88, and a PEG ratio of 0.07, significantly lower than its peers like Sun Pharma and Divi's Lab, despite underperforming the Sensex over the past year.

As of 26 May 2025, the valuation grade for Vivo Bio Tech has moved from attractive to very attractive, indicating a positive shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 9.33, an EV to EBITDA ratio of 5.88, and a PEG ratio of 0.07, all of which suggest that the stock is trading at a significant discount compared to its earnings growth potential.<BR><BR>In comparison to its peers, Vivo Bio Tech stands out with a much lower PE ratio than Sun Pharma (35.25) and Divi's Lab (79.33), both of which are categorized as expensive. Additionally, its EV to EBITDA ratio is significantly better than those of its peers, reinforcing the undervaluation narrative. While Vivo Bio Tech has underperformed the Sensex over the past year with a return of -5.27% compared to the Sensex's 7.60%, its strong valuation metrics suggest that it may present a compelling investment opportunity moving forward.

What is the technical trend for Vivo Bio Tech?

As of May 12, 2025, the trend is mildly bearish due to daily moving averages and monthly bearish indicators, despite some mildly bullish signals on the weekly charts, with the stock underperforming against the Sensex over the past few years.

As of 12 May 2025, the technical trend has changed from bearish to mildly bearish. The current stance is mildly bearish, driven primarily by the daily moving averages indicating a mildly bearish trend, while the monthly MACD and RSI are both bearish. The weekly MACD and KST show mildly bullish signals, but the overall sentiment remains cautious due to the bearish indicators on the monthly Bollinger Bands and the lack of a clear trend in Dow Theory. The stock has underperformed against the Sensex over the past year and three years, further supporting the bearish outlook.

Who are the top shareholders of the Vivo Bio Tech?

The top shareholders of Vivo Bio Tech are Cryptologic Systems Private Limited with 7.5% and Elite Class Asset Holdings Ltd with 7.25%. Individual investors hold a combined 35.48%, and there are no mutual funds or foreign institutional investors involved.

The top shareholders of Vivo Bio Tech include Cryptologic Systems Private Limited, which holds the highest promoter stake at 7.5%. Following closely is Elite Class Asset Holdings Ltd, the highest public shareholder, with a holding of 7.25%. Additionally, individual investors collectively hold 35.48% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company.

Has Vivo Bio Tech declared dividend?

No Dividend History Available